Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Annexon Biosciences Inc.

www.annexonbio.com

Latest From Annexon Biosciences Inc.

Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path

Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.

Financing Business Strategies

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018

The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.

Financing Business Strategies

Venture Funding Deals, August 2016

Derived from Strategic Transactions, Informa's premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced June through July 2016.

Commercial Business Strategies

VC Roundup: More Funds Raise Cash For Biotech; Morphic Closes $51.5m Series A

Five venture capital firms raised new funds to finance biopharma companies in June and five therapeutics developers closed early-stage funding rounds during the last week of June.

Companies Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Annexon Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Annexon Biosciences Inc.
  • Senior Management
  • Douglas Love, Pres. & CEO
    Jennifer Lew, EVP, CFO
    Ted Yednock, PhD, EVP, CSO
    Lesley Stolz, PhD, EVP, CBO
    Sanjay Keswani, EVP, CMO
  • Contact Info
  • Annexon Biosciences Inc.
    Phone: (650) 822-5500
    180 Kimball Way, 2nd Fl.
    Ste. 200
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register